Drug maker Dishman Pharmaceuticals & Chemicals today said its consolidated net profit for the year ended March 31, 2009, rose by 22.13 per cent to Rs 146.19 crore, over the same period last year.
The company had a net profit of Rs 119.70 crore for the same period ended March 2008, Dishman Pharmaceuticals said in a filing to the Bombay Stock Exchange.
Total income of the company rose to Rs 1,067.12 crore for the period ended March 2009, from Rs 804.44 crore for the same period last year.
The board has declared a dividend of Rs 1.20 a piece on the face value of Rs 2 per share for the financial year 2008-09.
Dishman Infrastructure (DIL) discontinued as wholly owned subsidiary of the Company. DIL has issued further shares to others in the month of March, 2009. Hence, company’s holding in DIL has decreased from 100 per cent to one per cent.
Shares of Dishman Pharmaceuticals & Chemicals settled at Rs 145.35, up 4.49 per cent on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app